Abstract
PurposeThis systematic review and meta-analysis aimed to evaluate the effect of sofosbuvir/daclatasvir (SOF/DCV) on mortality, the need for intensive care unit (ICU) admission or invasive mechanical ventilation (IMV) and clinical...
Highlights
COVID-19 remains one of the most prevalent diseases globally despite the best effort to contain them.[1]
This systematic review and meta-a nalysis aims to evaluate the effect of SOF/DCV on mortality, the need for intensive care unit (ICU) admission or invasive mechanical ventilation (IMV) and clinical recovery in patients with COVID-19
SOF/DCV and outcomes SOF/DCV administration was associated with reduced mortality (RR: 0.31 (0.12, 0.78)], p=0.013; I2: 0%, p=0.400)
Summary
COVID-19 remains one of the most prevalent diseases globally despite the best effort to contain them.[1]. SARS-CoV-2 is a positive-sense single-stranded RNA virus that relies on RNA-dependent RNA- polymerase (RdRp) for viral replication.[6] Sofosbuvir/daclatasvir (SOF/DCV) is a direct-acting antiviral drug that has been shown to inhibit RdRp of hepatitis C virus (HCV).[7 8] Preclinical studies indicate the potential activities of SOF and DCV on SARS-CoV-2 RdRp, the mixed results.[9 10] Several clinical studies indicate the potential benefit of SOF/DCV in patients with COVID-19.9 11 12 These drugs have relatively mild side effects and are affordable. This systematic review and meta-a nalysis aims to evaluate the effect of SOF/DCV on mortality, the need for intensive care unit (ICU) admission or invasive mechanical ventilation (IMV) and clinical recovery in patients with COVID-19
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
